List of Small Molecule Pharmaceuticals Companies in Georgia - 20

Accuitis Pharmaceuticals, Inc. is a US registered company with commercial operations located in Atlanta, GA. Accuitis is a participant in the Georgia Research Alliance Venture Lab program and our key technology was discovered by Emory University. We are engaged in the acquisition and development of pharmaceuticals targeting niche, orphan, and underserved disease states. Our lead product is a transformational first in class treatment for Rosacea.

Altesa is a clinical-stage pharmaceutical company dedicated to developing new treatments for age-old threats to human health: high-consequence viral infections. These infections are particularly severe in vulnerable people, including those with chronic health conditions, like lung diseases, as well as the elderly and many people in underserved communities. Altesa builds upon a proven, highly successful drug development platform that has already prevented countless deaths from the two most impactful pandemics of the past 100 years—HIV/AIDS and COVID-19. Our objective is to develop safe and effective antiviral medicines in simple oral dosage forms that, when prescribed for the right people at the right time, will halt the progression of infection before it becomes serious—or even prevent the infection altogether. This strategy extends the proven benefits of testing for viruses such as the flu or COVID-19, which have both caused suffering and death among vulnerable people but can be treated if properly diagnosed. Viral pathogens like these and others have plagued mankind for many thousands of years, but testing for and treating them is an effective strategy to blunt their impact and, ideally, to defeat them.

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company’s lead product candidate is AL001 for the treatment of Alzheimer’s and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient’s immunological system to Alzheimer’s. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

Athens Research and Technology, Inc. (ART) is a dynamic life science company and recipient of the Globe Award as Georgia's 2022 Exporter of the Year. Since our founding over three decades ago, we continue to proudly support the life sciences industry in the advancement of essential medical diagnostics and therapies. ART is renowned for defining the industry standard for native protein purification. We specialize in producing natural human and animal proteins critical to academic research and manufacturing in the Clinical Diagnostic, Cell Culture Media, and Standards/Calibration industries. Our custom purification programs support our long-standing distinguished industry partners as well as our growing base of inspired customers. Since 1986, ART products have been sought after by prominent academic researchers and biotech companies for high-impact research published in Nature, Science, & Cell journals. ART proteins have been crucial for Alzheimer's, Cancer, Cardiac, Pulmonary, and Covid-19 research. Envisioned by local physicians and a university of Georgia researcher, ART was one of the first Life Science start-ups to launch from the University of Georgia incubator. Since our inception, we have served as a model for success to many subsequent companies. We are committed to People, Purpose, & Proteins. People are at the core of our belief system. Our culture continues to attract great talent, developing the next generation of industry-leading Protein Chemists. Purpose is ingrained in our being, keeping quality proteins at the forefront of research for the world's most complex medical challenges. Our purpose overflows into the Athens, GA, community as we ensure the health and strength of our neighbors and the growth of our local economy. Proteins are the core of our success. After 36 years, our company holds a breadth of knowledge of proteins and purification processes, allowing us to purify even the most complex and least abundant proteins in the human body.

Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Dogwood is pioneering Halneuron®, a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain (CINP), cancer pain, and other pain indications. It is also developing the antiviral combination therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID (“LC”) and fibromyalgia (“FM”)

Dr. Reddy's Laboratories is a pharmaceutical company that specializes in pharmaceutical manufacturing and healthcare products.

FERMWORX is a biotechnology company that specializes in producing high-performance biopolymer-based and bio-based fermentation products, offering product development and toll manufacturing services with a focus on renewable and sustainable practices.

Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. We use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer. We also have a colorectal cancer program moving towards commercialization in foreign locations based on medical needs in those regions.

Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule kinase inhibitor therapeutics that modify Parkinson's disease and drive functional reversal inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.

At Kura Biotech, our dedication is grounded in the strong belief and conviction that we can generate a positive impact in the World by helping laboratories with their most complex challenges and by providing scientists with the fastest and the highest performing enzymes for sample preparation. After developing revolutionary solutions in toxicology through our Finden brand, we are now expanding our expertise to the genetics and proteomics industry with two new brands: Avenire and Blikka. We thrive to face challenges through our four core commitments: human connections, unlimited spirit, unapologetic standards, and give back will. Each year we contribute 2% of our revenues to the development of the community where we are located through three core fields: childhood, education, and environment. Where there is a will, there’s a way!

Micron Biomedical, Inc. is a clinical-stage biopharmaceutical company on a rapid path to bring to market drugs and vaccines that are formulated into a proprietary patch technology that simplifies and improves the way actives are delivered, stored, and distributed. This technology is designed to increase patient access to drugs and vaccines that would otherwise require expert injection and to improve safety and efficacy by skin targeting.

Founded in 1990, MVA Scientific Consultants is a leading full-service analytical microscopy laboratory offering customized testing solutions across industries such as environmental forensics, industrial hygiene, pharmaceuticals, and nanomaterials. Our expertise in microscopy supports regulatory compliance, quality assurance, litigation, and R&D projects. We are ISO/IEC 17025 accredited, cGMP compliant, DEA licensed, and FDA registered, ensuring high-quality reporting and strict client confidentiality. Visit our website to learn more about how MVA Scientific Consultants can assist you with your next project.

NeuroPn Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases with focus on chronic neuropathic pain and Parkinson’s disease. Developing Non-narcotic, Safe and Innovative Treatments for Neuropathic Pain NeuroPn is addressing the urgent opioid crisis and developing novel, safe, effective, and potentially disease modifying treatments for patients suffering from chronic pain. Developing Novel, Disease Modification Therapies for Parkinson’s Disease NeuroPn is aiming to transform treatments for neurodegenerative diseases and is developing innovative therapies with superior efficacy and improved safety profile over marketed drugs. NeuroPn approach has potential to halt or reverse Parkinson’s disease progression.

NeuroTrauma Sciences (NTS) is a biopharmaceutical company focused on developing therapies to treat the devastating effects of stroke and traumatic brain injury (TBI), including concussion. NTS is taking an innovative approach to the treatment of these conditions by addressing the fundamental underlying biological processes that enable the pathophysiological injury cascade.

Noramco, headquartered in Wilmington, Delaware, is a global leader in the production of controlled substances for the pharmaceutical industry, for medicines used to treat attention deficit hyperactivity disorder, pain, addiction, and for abuse-deterrent formulations. We realize our success through a keen focus on commercial and operational excellence as well as continuing strategic growth. Our global footprint includes Athens, GA, Wilmington, DE and Neuhausen, Switzerland. Specialists in controlled substance development and manufacturing, Noramco is a partner to the pharmaceutical industry: – Focusing on high-purity controlled substances – Leveraging intellectual property to devise the most efficient routes to APIs – Providing analytical data, chemical and physical properties, stability studies and regulatory assistance – Formulation friendly particle size grades and extended technical packages – Delivering DEA-compliant security and production capacity, from kilos to multi-ton supply – Supporting world-class supply security of controlled-substances, from schedule I to schedule III

Oncorx Pharmaceuticals is an early-stage pharmaceutical company developing high-affinity drugs that selectively target the P-glycoprotein/CD44/Integrin β1 protein complex that is overexpressed on the surface of therapy-resistant tumors. Activation of α5β1 integrin plays an important role in regulating cytoskeletal reorganization, F-actin polarization, the epithelial-to-mesenchymal transition, anchorage-independent tumor cell growth, and tumor cell apoptosis. Currently available cancer therapies are targeted to primary, untransformed tumor cells and are not effective in treating resistant transformed tumors that have entirely different cell surface receptor targets and actin cytoskeletal organization. Oncorx is developing oncology drugs that not only target resistant tumors, but also effectively penetrate the blood-brain-barrier to reach the tumor sanctuary in the brain. Numerous clinical studies have demonstrated that patient survival is strongly dependent upon the time it takes for tumors to reach the brain from their primary site in the body.

Pharma Tech Industries (PTI) is a pharmaceutical contract manufacturing organization offering fully-integrated supply chain support and customized production services to many of the most trusted pharmaceutical and wellness companies in the world.

Saol Therapeutics (pronounced "Sail") is a privately held, clinical-stage, pharmaceutical company with operations in Roswell, GA, Dublin, Ireland and Hamilton, Bermuda. The company is focused on development activity in CNS disorders such as pain management and spasticity and orphan diseases. Saol is committed to providing and advancing therapeutic options for patients and the physicians treating these populations and currently has two Phase 2 trials and one Phase 3 trail underway in the United States.

Sebela Pharmaceuticals is a U.S. pharmaceutical company with a market-leading position in Gastroenterology and a focus on innovation in Women’s Health. Our Vision is to build the leading Gastroenterology company in the U.S., with a complementary focus on innovation in Women’s Health, premised on our expertise in pharmaceutical development and commercialization. We value dedication, energy, and enthusiasm, and we focus on innovation and results while striving to achieve our corporate mission and vision. Sebela Pharmaceuticals is committed to cultivating an inclusive environment where all employees are treated with respect. We accomplish this by fostering a culture of diversity, equity and inclusion, which is essential to innovation and continuous improvement. Sebela operates from three locations with offices in Roswell, Georgia, Braintree, MA and headquarters in Dublin, Ireland.